만성 신장 질환을 위한 요중 바이오마커 기반 진단 및 모니터링 시스템과 SGLT2 억제제의 실제 효과
소변 바이오마커 기반 만성 신장 질환 진단 및 모니터링 시스템과 SGLT2 억제제 엠파글리플로진을 이용한 예방 치료
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.
No investigational product is assigned, and medical practice or prescription patterns are not altered.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.
The project integrates translational and clinical components:
- validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
- evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.
A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.
The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.
Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.
The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Carlos Martínez Salgado, PhD
- 전화번호: +34616129633
- 이메일: carlosms@usal.es
연구 장소
-
-
-
Salamanca, 스페인
- 모병
- Hospital Universitario de Salamanca
-
연락하다:
- Carlos Martínez Salgado, PhD
- 전화번호: +34616129633
- 이메일: carlosms@usal.es
-
연락하다:
- Pilar Fraile Gómez, MD, PhD
- 전화번호: +34923291100
- 이메일: pilarfg@usal.es
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Participants with chronic kidney disease (CKD) stages 2-4.
설명
Inclusion Criteria:
- ≥18 years old
- Diagnosed with chronic kidney disease (KDIGO stages 2-4)
- Life expectancy ≥12 months
- Available clinical and laboratory data in the electronic medical record
Exclusion Criteria:
- Current or recent renal replacement therapy or kidney transplantation
- End-stage renal disease
- Participation in interventional trials that may affect outcomes
- Allergy or intolerance to SGLT2i (for exposed cohort)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Empagliflozin Treatment Group
Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety. |
Oral empagliflozin (10-25 mg daily) for 12 months |
|
Control group
Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in urinary biomarker panel expression (proteomic fingerprint)
기간: Baseline, 6 months, 12 months
|
Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels. |
Baseline, 6 months, 12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR)
기간: Baseline, 6 months, 12 months
|
Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment. |
Baseline, 6 months, 12 months
|
|
Histopathological improvement of renal tissue (animal study)
기간: Monthly up to 9 months
|
Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin. |
Monthly up to 9 months
|
|
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
기간: From baseline to 12 months
|
Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment. Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator. |
From baseline to 12 months
|
|
Change in estimated glomerular filtration rate (eGFR)
기간: From baseline to 12 months
|
Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation. |
From baseline to 12 months
|
|
Change in serum creatinine
기간: From baselinte to 12 months
|
hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL). |
From baselinte to 12 months
|
|
Change in urinary albumin-to-creatinine ratio
기간: From baseline to 12 months
|
Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine). |
From baseline to 12 months
|
|
Change in serum electrolyte levels
기간: From baseline to 12 months
|
Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L). |
From baseline to 12 months
|
|
Change in liver function tests
기간: From baseline to 12 months
|
Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L). |
From baseline to 12 months
|
|
Change in glycated hemoglobin (HbA1c)
기간: From baseline to 12 months.
|
Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%). |
From baseline to 12 months.
|
|
Change in hematological parameters
기간: From baseline to 12 months
|
Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing. |
From baseline to 12 months
|
|
Change in blood pressure
기간: From baseline to 12 months
|
Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg). |
From baseline to 12 months
|
|
Change in body weight
기간: From baseline to 12 months
|
Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg). |
From baseline to 12 months
|
|
Discontinuation due to treatment intolerance
기간: From baseline to 12 months
|
Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting. |
From baseline to 12 months
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Carlos Martínez Salgado, PhD, University of Salamanca
- 수석 연구원: Pilar Fraile Gómez, MD, PhD, University of Salamanca
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PI25/00053
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
IPD 공유 기간
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
IPD 공유 액세스 기준
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ANALYTIC_CODE
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .